Abstract
Purpose
Despite the detrimental impact of chronic (chemotherapy-induced) peripheral neuropathy PN on patients’ lives, treatment options remain limited. We examined the association between mindfulness and chronic PN symptom severity and impairments in related patient-reported outcomes (PROs) among colorectal cancer (CRC) patients up to 2 years after diagnosis.
Methods
Newly diagnosed stage I–IV CRC patients from four Dutch hospitals were eligible for participation. Patients (N = 336) completed a questionnaire on mindfulness (MAAS) at 1 year after diagnosis, and questionnaires on sensory (SPN) and motor peripheral neuropathy (MPN) (EORTC QLQ-CIPN20), anxiety and depressive symptoms (HADS), sleep quality (PSQI), and fatigue (EORTC QLQ-C30) before initial treatment (baseline) and 1 and 2 years after diagnosis.
Results
At 1-year follow-up, 115 patients (34%) and 134 patients (40%), respectively, reported SPN or MPN symptoms. In multivariable regression analyses, higher mindfulness at 1-year follow-up was associated with less severe MPN and fewer anxiety and depressive symptoms, better sleep quality, and less fatigue. Of the patients with SPN or MPN at 1-year follow-up, symptoms had not returned to baseline level at 2-year follow-up in 59 (51%) and 72 (54%) patients, respectively. In this subgroup, higher mindfulness was associated with less severe SPN and fewer anxiety symptoms, depressive symptoms, and fatigue at 2-year follow-up.
Conclusion
Mindfulness was associated with less severe PN and better related PROs among CRC patients with chronic PN. More research is needed to examine the role of mindfulness in the transition from acute to chronic PN.
Keywords: Colorectal cancer, Peripheral neuropathy, Mindfulness, Anxiety symptoms, Depressive symptoms, Patient-reported outcomes
Introduction
Peripheral neuropathy (PN) is a common and disabling condition in many cancer patients. In colorectal cancer (CRC), PN is most often caused by the administration of oxaliplatin, primarily leading to sensory peripheral neuropathy (SPN) symptoms (i.e., numbness, tingling, and neuropathic pain in the hands or feet) and motor peripheral neuropathy (MPN) symptoms (i.e., impaired movements, distal weakness, and cramps) [1, 2]. Although chemotherapy-induced PN resolves in the majority of patients after treatment, it becomes a chronic condition in 30% of cancer patients [2]. In addition, PN has been found among cancer patients who did not undergo chemotherapy [3], suggesting that the cancer itself may also be involved in PN development.
PN negatively impacts patient-reported outcomes (PROs), including psychological distress, sleep quality, and fatigue [4–7]. For example, among CRC survivors 2–12 years after diagnosis, we previously showed that survivors with high chemotherapy-induced PN reported more anxiety and depressive symptoms and more fatigue compared with survivors with low chemotherapy-induced PN [5]. In addition, in a study using the same study population as the current study, we found that PN was negatively associated with sleep quality over time [8]. There is thus a large need for effective treatments for (chronic) PN, which are, unfortunately, still limited [9].
In parallel to other chronic pain-related syndromes, psychosocial factors likely play an important role in chronic PN. According to biopsychosocial models of chronic pain, including the well-supported fear-avoidance model, future pain is strongly influenced by the way patients interpret their pain sensations [10, 11]. Maladaptive pain cognitions, such as pain catastrophizing, promote hypervigilance to symptoms and repetitious avoidance of activities, which may result in the persistence and even exacerbation of symptoms. Just as psychological factors can contribute to this negative pain circle [12, 13], some psychological factors, such as mindfulness, may also be able to break through it, and may therefore lead to lower pain severity and less impairments in related PROs [14, 15].
Mindfulness is defined as a non-elaborative, non-judgmental, present-centered awareness in which each thought, feeling, or sensation that arises in the attentional field is acknowledged and accepted as it is [16]. It can be seen as both a dispositional trait that varies from individual to individual, as well as a trainable skill [17]. Among patients with chronic pain, mindfulness is associated with better pain outcomes, such as lower pain severity and less pain interference [18–21], yet little is known about the association between mindfulness and PN. To our knowledge, only one study has been conducted so far. In this study among breast and gastrointestinal cancer survivors with chronic neuropathic pain, higher mindfulness was cross-sectionally associated with lower pain intensity; less pain catastrophizing, pain interference, and depression; and better mental health-related quality of life (HRQoL) [22]. However, it is unclear whether mindfulness is cross-sectionally associated with PN in general (including painful PN) among cancer patients and whether mindfulness is also prospectively associated with PN. Therefore, we will examine the cross-sectional and prospective association between mindfulness and chronic PN symptom severity and related PROs (i.e., psychological distress, sleep quality, and fatigue) in CRC patients. We hypothesize that mindfulness, measured at 1-year follow-up, will be associated with PN symptom severity and related PROs at 1- and 2-year follow-up among our sample of CRC patients.
Methods
Setting and participants
This study is based on data from the PROCORE study, a prospective, population-based study aimed to examine the longitudinal impact of CRC and its treatment on patient-reported outcomes. Details of the data collection have been described elsewhere [8]. In short, data was collected through PROFILES, a registry for the physical and psychosocial impact of cancer and its treatment [23]. PROFILES is directly linked to the Netherlands Cancer Registry (NCR), which collects data from all newly diagnosed cancer patients in the Netherlands [24].
Patients were recruited from four Dutch hospitals: Elisabeth-TweeSteden Hospital, Catharina Hospital, Elkerliek Hospital, and Máxima Medical Centre. Eligible patients newly diagnosed with primary CRC between January 2016 and January 2019 were invited. Exclusion criteria were previous diagnosis with cancer, except for basal cell carcinoma of the skin, cognitive impairments, and not being able to read or write Dutch. All patients were included shortly after diagnosis, before start of treatment. In practice, some patients who were previously diagnosed with cancer and those who already started treatment were also included. Parallel to previous PROCORE publications [25, 26], patients were excluded for analysis if they (1) were previously diagnosed with cancer and reported baseline EORTC QLQ-CIPN20 scores > 0 or (2) already started chemotherapy.
Data collection
Eligible patients were invited by their research nurse or case manager. Patients received an information package, including an information letter, informed consent form, and the first questionnaire. Follow-up questionnaires were sent 4 weeks after surgery (when applicable), and 1 and 2 years after diagnosis. The questionnaire 4 weeks after surgery was not included in the current analyses, as it did not include PN. The PROCORE study was approved by the certified Medical Ethic Committee of Medical Research Ethics Committees United (registration number NL51119.060.14).
Sociodemographic and clinical characteristics
Patients’ sociodemographic (i.e., age, sex) and clinical (i.e., cancer type, clinical stage, treatment) information was available from the NCR [24]. Questions on partner status and educational level were added to the questionnaire. Comorbidity was assessed with the adapted Self-Administered Comorbidity Questionnaire (SCQ) [27].
Mindfulness
Dispositional mindfulness was measured at 1-year follow-up using the Mindful Attention Awareness Scale (MAAS) [28]. The MAAS is a validated 15-item scale assessing awareness of and attention to what is occurring in the present, which is a core characteristic of dispositional mindfulness. Items are answered on a 6-point Likert scale ranging from (1) almost always to (6) almost never. The MAAS is scored by calculating the mean of the items, with higher scores indicating greater dispositional mindfulness.
Peripheral neuropathy
The EORTC QLQ-CIPN20 [29] was used to assess PN severity, both in patients with and without chemotherapy, as PN has also been found among CRC patients who did not receive chemotherapy [3]. The EORTC QLQ-CIPN20 assesses the extent in which sensory, motor, and autonomic symptoms of PN were experienced during the past week. In the current study, we solely focused on SPN and MPN, and not autonomic PN, as SPN and MPN are most prevalent in CRC, and we previously only found an increase in SPN and MPN after treatment [25]. EORTC QLQ-CIPN20 items are measured on a Likert scale ranging from (1) not at all to (4) very much. Scores were transformed to a 0–100 scale, with higher scores representing higher symptom severity [30]. The SPN scale was calculated excluding the item on hearing problems [26], as it has been found unlikely to accurately identify PN [31].
Anxiety and depressive symptoms
The Hospital Anxiety and Depression Scale (HADS) was used to assess anxiety and depressive symptoms [32]. The items, which assess anxiety and depressive symptoms in the last week, are answered on a four-point Likert scale. Total scores for both scales range from 0 to 21, with higher scores representing more anxiety and depressive symptoms.
Sleep quality
Sleep quality was measured using the Pittsburgh Sleep Quality Index (PSQI) [33]. It consists of 19 items assessing seven components of sleep in the previous month (e.g., subjective sleep quality, sleep latency, sleep duration, and habitual sleep efficiency). A global PSQI score is calculated by the components and ranges from 0 to 21, with higher score representing worse sleep quality.
Fatigue
The fatigue subscale of the EORTC QLQ-C30 was used to assess fatigue [34]. The fatigue subscale consists of three items, asking patients to what extent they needed to rest, felt weak, and were tired. Items are scored on a Likert scale ranging from (1) not at all to (4) very much. Scores were linearly transformed to a 0–100 range, with higher scores representing more fatigue [30].
Statistical analyses
NCR data on patient characteristics enabled us to compare eligible patients and respondents, using t tests for continuous variables and chi-squared (or Fisher’s exact) tests for categorical variables. Similarly, differences in patient characteristic were compared between (1) patients with SPN and those without SPN at 1-year follow-up and (2) patients with MPN and those without MPN at 1-year follow-up. Patients were considered to have SPN or MPN if they either developed SPN or MPN symptoms (i.e., EORTC QLQ-CIPN20 SPN/MPN subscale score = 0 at baseline and > 0 at 1-year follow-up) or experienced a worsening of their existing SPN or MPN symptoms at 1-year follow-up (i.e., > 0 difference between EORTC QLQ-CIPN20 SPN/MPN subscale score at baseline and 1-year follow-up) [35].
To provide more insight in the PN symptoms of the patients in this study, frequency distributions were calculated in patients with SPN (or MPN) at 1-year follow-up and patients whose SPN (or MPN) symptoms had not returned to baseline level at 2-year follow-up.
Finally, hierarchical regression analyses were done to examine the association between mindfulness at 1-year follow-up and SPN (or MPN) severity and psychological distress, sleep quality, and fatigue at 1- and 2-year follow-up. In the first step, solely mindfulness was entered in the model. In the second step, a priori-determined sociodemographic (i.e., age, sex, partner status (yes/no), and educational level (high vs. low/medium)) and clinical confounding variables (i.e., tumor type (colon vs. rectum(sigmoid)), cancer stage (stage III/IV vs. I/II), radiotherapy, oxaliplatin, and capecitabine) were added.
All analyses were performed using SPSS (IBM SPSS Statistics for Windows, Version 24.0 Armonk, NY: IBM Corps, USA). A p value < 0.05 was considered statistically significant.
Results
Patient characteristics
Of the 713 CRC patients who were invited to the study, 68% (n = 483) completed the questionnaire at baseline, 52% (n = 374) at 1-year follow-up, and 49% (n = 347) at 2-year follow-up. A flow chart of the study has been published previously [8]. Compared with all patients eligible for participation, respondents were younger, more often male, and less often diagnosed with rectosigmoid cancer. Furthermore, they were less likely to undergo surgery, more likely to receive chemotherapy, and more often had stage III cancer and less often stage IV cancer (data not shown). While baseline and 1-year follow-up questionnaires were completed by 374 patients, 336 patients were included in the analyses of this study as six patients had missing data on the EORTC QLQ-CIPN20 and 32 patients were previously diagnosed with cancer and reported baseline EORTC QLQ-CIPN20 scores > 0 and/or had already started chemotherapy at time of baseline.
Patients with SPN symptoms at 1-year follow-up (n = 115, 34%) were on average younger, less likely to have stage I or II cancer, and more likely to have stage III cancer, and they received chemotherapy and specifically oxaliplatin more often compared with patients without SPN (Table 1). Patients with MPN (n = 134, 40%) were more often female, less often had no comorbidities, and more often at least two comorbidities. Furthermore, they more often had osteoarthritis, and more often received chemotherapy, specifically oxaliplatin, compared with patients without MPN.
Table 1.
Baseline sociodemographic and clinical characteristics of colorectal cancer patients stratified by the presence of sensory and motor peripheral neuropathy at 1-year follow-up
| Sensory peripheral neuropathy | Motor peripheral neuropathy | |||
|---|---|---|---|---|
| Yes (N = 115) | No (N = 221) | Yes (N = 134) | No (N = 202) | |
| Age (mean, SD) | 65.1 (9.0)* | 67.3 (8.5) | 65.3 (9.5)* | 67.3 (8.0) |
| Female sex | 44 (38%) | 85 (39%) | 62 (46%)* | 67 (33%) |
| Partner (yes) | 95 (83%) | 191 (86%) | 111 (83%) | 175 (87%) |
| Education levela | ||||
| Low | 13 (11%) | 17 (8%) | 11 (8%) | 19 (10%) |
| Medium | 67 (58%) | 142 (65%) | 84 (63%) | 125 (62%) |
| High | 35 (30%) | 60 (27%) | 38 (29%) | 57 (28%) |
| Tumor location | ||||
| Colon | 85 (74%) | 157 (71%) | 93 (69%) | 149 (74%) |
| Rectum/rectumsigmoid | 30 (26%) | 64 (29%) | 41 (31%) | 53 (26%) |
| TNM stage | ||||
| I | 19 (17%)‡ | 87 (39%) | 35 (26%) | 71 (35%) |
| II | 22 (19%) | 71 (32%) | 37 (28%) | 56 (28%) |
| III | 70 (61%) | 56 (25%)6 | 56 (42%) | 70 (35%) |
| IV | 4 (4%) | (3%) | 6 (5%) | 4 (2%) |
| Unknown | 0 (0%) | 1 (1%) | 0 (0%) | 1 (1%) |
| Tumor differentiation grade | ||||
| Well differentiated | 0 (0%) | 2 (1%) | 0 (0%) | 2 (1%) |
| Moderately differentiated | 93 (81%) | 178 (81%) | 115 (86%) | 156 (77%) |
| Poorly differentiated | 6 (5%) | 11 (5%) | 3 (2%) | 14 (7%) |
| Unknown | 16 (14%) | 30 (14%) | 16 (12%) | 30 (15%) |
| Radiotherapy (yes) | 21 (18%) | 29 (13%) | 18 (13%) | 32 (16%) |
| Chemotherapy | ||||
| No | 51 (44%)‡ | 181 (82%) | 83 (62%)† | 149 (74%) |
| Capecitabine | 10 (9%) | 18 (8%) | 9 (7%) | 19 (9%) |
| Oxaliplatin | 54 (47%) | 22 (10%) | 42 (31%) | 34 (17%) |
| Surgery (yes) | 112 (97%) | 217 (98%) | 131 (98%) | 198 (98%) |
| Number of comorbidities | ||||
| None | 34 (30%) | 60 (27%) | 33 (25%) | 61 (31%) |
| One | 43 (38%) | 70 (32%) | 47 (35%) | 66 (33%) |
| Two or more | 37 (32%) | 89 (41%) | 54 (40%) | 72 (36%) |
| Comorbidities associated with PNb | ||||
| Osteoarthritis | 26 (23%) | 43 (20%) | 35 (26%)† | 34 (17%) |
| Rheumatoid arthritis | 6 (5%) | 10 (5%) | 7 (5%) | 9 (5%) |
| Diabetes mellitus | 13 (11%) | 17 (8%) | 13 (10%) | 17 (9%) |
Variables may deviate from 100% due to rounding off. Significant difference between either patients with SPN and those without SPN at 1-year follow-up, or patients with MPN and those without MPN at 1-year follow-up at *p < 0.05; †p < 0.01; ‡p < 0.001
SD standard deviation, PN peripheral neuropathy
aEducation: low (no or primary school); medium (lower general secondary education or vocational training); high (pre-university education, high vocational training, university)
bMost frequent comorbidities associated with peripheral neuropathy
PN
Among patients who reported SPN at 1-year follow-up, tingling fingers or hands (46%), tingling toes or feet (40%), numbness in toes or feet (38%), and numbness in fingers or hands (32%) were most frequently reported. In addition, while among 33% (n = 38) of patients SPN symptoms had returned to baseline at 2-year follow-up, 51% (n = 59) continued to have SPN levels above baseline (n = 18 missing). Specifically, SPN symptoms improved slightly compared to 1-year follow-up, but did not return to baseline in 28% (n = 32) of patients, remained stable in 11% (n = 13), and worsened in 12% (n = 14). Patients reported improvements primarily in tingling toes or feet (37%) and tingling fingers or hands (38%), and deterioration in problems standing or walking because of difficulty feeling the ground under their feet (12%) and numbness in toes or feet (11%).
Among patients with MPN at 1-year follow-up, difficulty opening a jar or bottle because of weakness in hands (62%), difficulty manipulating small objects with fingers (50%), difficulty climbing stairs or getting up out of a chair because of weakness in legs (42%), and cramps in hands (35%) were most frequently reported. At 2-year follow-up, MPN symptoms had returned to baseline in 33% (n = 44) of patients, whereas symptoms had not returned to baseline in 54% (n = 72, n = 18 missing). Specifically, during that year, symptoms had improved somewhat in 22% of patients, remained stable in 16%, and worsened in 16%. Improvements were mainly reported in difficulty opening a jar or bottle because of weakness in hands (25%) and difficulty manipulating small objects with fingers (22%), while deteriorations were mainly reported in cramps in feet (13%) and cramps in hands (10%).
Mindfulness as a predictor of PN severity and related PROs
At 1-year follow-up, mindfulness was not significantly associated with SPN symptom severity, while higher mindfulness was associated with less severe MPN after controlling for sociodemographic and clinical confounders (Table 2). Mindfulness explained 3% of the variance in MPN symptom severity. Higher mindfulness was also associated with fewer anxiety and depressive symptoms, better sleep quality, and less fatigue among patients with SPN or MPN. Among patients with SPN or MPN, the variance explained by mindfulness was lowest for sleep quality (5% and 6%, respectively) and highest for anxiety symptoms (41% and 47%, respectively).
Table 2.
Association between mindfulness and PN symptom severity and related PROs among patients with (A) SPN and (B) MPN at 1-year follow-up
| PNa severity | Anxiety symptoms | Depressive symptoms | Sleep quality | Fatigue | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| β | Adj R2 | β | Adj R2 | β | Adj R2 | β | Adj R2 | β | Adj R2 | |
| (A) Sensory peripheral neuropathy | ||||||||||
| Step 1 | ||||||||||
| Mindfulness | − .11 | − .67‡ | − .56‡ | − .27† | − .37‡ | |||||
| .00 | .44b | .30b | .06b | .13b | ||||||
| Step 2 | ||||||||||
| Mindfulness | − .15 | − .66‡ | − .54‡ | − .22* | − .37‡ | |||||
| Age | − .17 | .03 | .02 | − .20* | − .16 | |||||
| Sex (female) | − .04 | .16* | .04 | .23* | .04 | |||||
| Partner (yes) | .06 | .12 | .11 | .19 | .13 | |||||
| Educational level (high) | − .22* | − .14 | − .11 | − .26† | − .15 | |||||
| Tumor type (colon) | .29* | − .04 | − .08 | − .02 | .03 | |||||
| Stage (III and IV) | − .15 | .04 | − .10 | − .11 | − .14 | |||||
| Radiotherapy | − .21 | − .09 | .15 | .14 | − .01 | |||||
| Chemotherapy—oxaliplatin | .59‡ | − .08 | − .09 | .02 | .14 | |||||
| Chemotherapy—capecitabine | .12 | .10 | − .02 | .00 | .20 | |||||
| .25b | .48b | .31b | .17b | .16b | ||||||
| (B) Motor peripheral neuropathy | ||||||||||
| Step 1 | ||||||||||
| Mindfulness | − .16 | − .72‡ | − .56‡ | − .28† | − .37‡ | |||||
| .02 | .51b | .31b | .07b | .13b | ||||||
| Step 2 | ||||||||||
| Mindfulness | − .18* | − .70‡ | − .57‡ | − .26† | − .37‡ | |||||
| Age | .04 | − .03 | − .06 | − .19* | − .15 | |||||
| Sex (female) | .05 | .07 | − .21* | .05 | − .14 | |||||
| Partner (yes) | .11 | .06 | .01 | .15 | .06 | |||||
| Educational level (high) | − .06 | − .14* | − .18* | − .19 | − .09 | |||||
| Tumor type (colon) | − .04 | − .02 | − .12 | − .10 | − .13 | |||||
| Stage (III and IV) | − .13 | − .08 | − .11 | − .09 | .05 | |||||
| Radiotherapy | .02 | − .04 | .11 | .24 | − .01 | |||||
| Chemotherapy—oxaliplatin | .39† | − .02 | − .12 | .03 | − .10 | |||||
| Chemotherapy—capecitabine | .16 | − .03 | .02 | − .21 | .20* | |||||
| .07b | .52b | .36b | .11b | .17b | ||||||
PN peripheral neuropathy, PROs patient-reported outcomes, SPN sensory peripheral neuropathy, MPN motor peripheral neuropathy, Adj adjusted
*Significant at p < 0.05
†Significant at p < 0.01
‡Significant at p < 0.001
aAmong patients with SPN (A), the dependent variable is the sensory scale of the EORTC QLQ-CIPN20 (without the item on hearing problems), while among patients with MPN (B), the dependent variable is the motor scale of the EORTC QLQ-CIPN20
bChange in adjusted R2 is significant
Next, we examined whether mindfulness at 1-year follow-up was prospectively associated with PN symptom severity and related PROs at 2-year follow-up (Table 3). After controlling for sociodemographic and clinical confounders, mindfulness was significantly associated with SPN symptom severity, but not with MPN symptom severity. Mindfulness explained 8% of the variance in SPN symptom severity. Higher mindfulness was also associated with fewer anxiety and depressive symptoms and less fatigue, but no longer with sleep quality in patients whose SPN or MPN symptoms did not return to baseline level. Among patients with SPN or MPN, the variance explained by mindfulness was lowest for fatigue (20% and 15%, respectively) and highest for anxiety symptoms (45% and 33%, respectively).
Table 3.
Prospective association between mindfulness at 1-year follow-up and PN symptom severity and related PROs at 2-year follow-up among patients with (A) SPN and (B) MPN
| PNa severity | Anxiety symptoms | Depressive symptoms | Sleep quality | Fatigue | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| β | Adj R2 | β | Adj R2 | β | Adj R2 | β | Adj R2 | β | Adj R2 | |
| (A) Sensory peripheral neuropathy | ||||||||||
| Step 1 | ||||||||||
| Mindfulness | − .24 | − .68‡ | − .49‡ | − .20 | − .43† | |||||
| .04 | .45b | .22 | .02 | .17b | ||||||
| Step 2 | ||||||||||
| Mindfulness | − .30* | − .73‡ | − .51‡ | − .13 | − .49† | |||||
| Age | − .25 | − .09 | − .10 | − .39† | − .18 | |||||
| Sex (female) | .03 | .07 | .08 | .11 | − .08 | |||||
| Partner (yes) | .18 | .23 | .25 | .03 | .13 | |||||
| Educational level (high) | − .14 | .06 | .04 | − .18 | − .07 | |||||
| Tumor type (colon) | .28 | − .06 | .02 | − .10 | − .14 | |||||
| Stage (III and IV) | − .14 | .16 | .01 | − .47* | − .10 | |||||
| Radiotherapy | .01 | − .22 | .08 | .14 | .19 | |||||
| Chemotherapy—oxaliplatin | .36 | − .09 | − .07 | .28 | .16 | |||||
| Chemotherapy–capecitabine | .07 | .06 | − .03 | .09 | .16 | |||||
| .09 | .47b | .17b | .20b | .17b | ||||||
| (B) Motor peripheral neuropathy | ||||||||||
| Step 1 | ||||||||||
| Mindfulness | − .20 | − .63‡ | − .45‡ | − .25* | − .40† | |||||
| .03 | .39b | .19b | .05b | .15b | ||||||
| Step 2 | ||||||||||
| Mindfulness | − .22 | − .61‡ | − .41† | − .23 | − .41† | |||||
| Age | .04 | − .09 | − .13 | − .28* | − .21 | |||||
| Sex (female) | − .14 | − .01 | − .20 | − .24 | − .36† | |||||
| Partner (yes) | .01 | − .01 | − .11 | .08 | − .06 | |||||
| Educational level (high) | .12 | .01 | .16 | − .08 | .05 | |||||
| Tumor type (colon) | − .20 | − .08 | − .19 | − .20 | − .27 | |||||
| Stage (III and IV) | − .17 | − .04 | .00 | − .27 | − .17 | |||||
| Radiotherapy | .08 | − .13 | .06 | .12 | .29 | |||||
| Chemotherapy—oxaliplatin | .20 | .14 | − .22 | .14 | .00 | |||||
| Chemotherapy—capecitabine | .22 | − .02 | − .05 | .02 | .06 | |||||
| .01 | .37b | .16b | .10 | .23b | ||||||
PN peripheral neuropathy, PROs patient-reported outcomes, SPN sensory peripheral neuropathy, MPN motor peripheral neuropathy, Adj adjusted
*Significant at p < 0.05
†Significant at p < 0.01
‡Significant at p < 0.001
aAmong patients with SPN (A), the dependent variable is the sensory scale of the EORTC QLQ-CIPN20 (without the item on hearing problems), while among patients with MPN (B), the dependent variable is the motor scale of the EORTC QLQ-CIPN20
bChange in adjusted R2 is significant
Discussion
In this prospective, population-based study among CRC patients, we examined the cross-sectional and prospective association between mindfulness and chronic PN symptom severity and impairments in related PROs. We first showed that 34% of patients developed SPN or experienced a worsening of their existing SPN at 1-year follow-up, of whom 51% still reported SPN levels above baseline level at 2-year follow-up. Regarding MPN, development or worsening of existing symptoms was reported by 40% of patients, of whom 54% still reported MPN levels above baseline level at 2-year follow-up. Interestingly, 12–16% of patients reported worsening of symptoms at 2-year follow-up compared with 1-year follow-up. While coasting—the phenomenon that CIPN symptoms continue to worsen for 3 months after discontinuation of chemotherapy—has been found among patients treated with oxaliplatin [36], our patients had already completed their chemotherapy for ≥ 4 months at 1-year follow-up. Therefore, the worsening of symptoms at 2-year follow-up is likely related to older age and age- and PN-related comorbidities (e.g., rheumatoid arthritis, diabetes mellitus). Since we only have data on chemotherapy as primary treatment, it is also unknown whether patients may have undergone additional chemotherapy (e.g., for recurrent disease), which could exacerbate existing PN symptoms.
We hypothesized that mindfulness, measured at 1-year follow-up, would be associated with PN symptom severity and related PROs at 1- and 2-year follow-up. Results showed that higher mindfulness at 1-year follow-up was cross-sectionally associated with less severe MPN and fewer anxiety and depressive symptoms, better sleep quality, and less fatigue, and prospectively with less severe SPN and less anxiety symptoms, depressive symptoms, and fatigue. Only one previous study examined the association between mindfulness and PN. While this study focused on neuropathic pain, results were in line with our findings; mindfulness was negatively correlated with pain intensity and depression, and positively correlated with mental HRQoL [22]. Our findings regarding the association between mindfulness and PN symptom severity were not completely in line with our hypotheses: mindfulness was only associated with MPN symptom severity at 1-year follow-up and with SPN symptom severity at 2-year follow-up. We find it difficult to offer a sensible explanation for this surprising finding. It has previously been hypothesized that chemotherapy-induced PN during chemotherapy is primarily caused by the neurotoxic effects of the chemotherapeutic agent, while chronic chemotherapy-induced PN is primarily influenced by psychological factors that maintain chemotherapy-induced PN symptoms [37], and on which mindfulness may exerts its effect [15]. At 1-year follow-up, PN may not have been chronic for all patients, as some patients only completed their chemotherapy 4 or 5 months earlier. This may explain why we only found an association between mindfulness and SPN symptom severity at 2-year follow-up and not at 1-year follow-up. The finding that oxaliplatin was not related to SPN symptom severity at 2-year follow-up is also in line with the beforementioned hypothesis on the role of psychological versus neurotoxic factors in chronic PN. However, it could also be an indication of good patient care. Patients may have been closely monitored for early signs of PN and were given dose reduction or changes in chemotherapy doses or regimen could have been made when PN occurred, reducing the chance of long-lasting PN [2, 38]. In contrast to the hypothesis of psychological factors on chronic PN, mindfulness was only associated with MPN symptom severity at 1-year follow-up. However, weakness in hands and weakness in legs were among the top MPN symptoms reported at 1-year follow-up. At that time, these symptoms may still be a direct consequence of the cancer and its treatment, rather than reflect actual MPN. This could explain why we found an association between mindfulness and MPN symptom severity at 1-year follow-up, but not at 2-year follow-up. More research is needed to examine the role of psychological factors—including mindfulness—versus neurotoxic factors, both in acute and chronic PN. Nevertheless, while mindfulness was not associated with MPN symptom severity at 2-year follow-up, it was still associated with better related PROs among patients with MPN.
The association between mindfulness and PN symptom severity and related PROs may be explained through catastrophizing. Catastrophizing can be characterized by the perceived lack of control over (pain) symptoms, rumination, magnification of their consequences, and the expectation of negative outcomes [22]. It is a key variable in the fear-avoidance model [10, 11] and has been found to account for 7–31% of the variance in pain severity [39]. This maladaptive coping strategy promotes hypervigilance and avoidance of activities, causing increased distress and functional disability, which eventually leads to further future pain and impairments in related PROs. Mindfulness may interrupt this fear-avoidance cycle through reducing catastrophizing [15, 22]. In the study among cancer survivors with chronic neuropathic pain [22], mindfulness acted as a moderator in the association between pain intensity and pain catastrophizing. That is, among cancer survivors with high levels of pain, mindfulness counteracted patients’ tendency to catastrophize. This may then make patients with high mindfulness less likely to avoid activities they expect to cause pain—or PN symptoms—which lowers their risk of developing (further) emotional distress and functional disability. Indeed, in the previously mentioned study among cancer survivors with neuropathic pain [22], mindfulness also moderated the association between pain intensity and the interference of pain.
Causality cannot be determined in our study, and, to our knowledge, the effectiveness of a mindfulness-based intervention in reducing PN or improving PROs has not yet been examined among cancer patients with (chronic) PN. In other chronic pain-related conditions, mindfulness-based interventions have been shown promising [18, 40, 41]. For example, among patients with painful diabetic peripheral neuropathy whose pharmacotherapy had been optimized, treatment with mindfulness-based stress reduction resulted in reduced pain intensity, pain catastrophizing, depression, and perceived stress, and better HRQoL compared with usual care [40]. Future research is needed to examine the effectiveness of such mindfulness-based interventions in chronic PN.
Several limitations should be mentioned. First, while important determinants of PN symptom severity, we had no data on chemotherapy dosage, number of cycles, and dose reductions [2]. Also, we only used the patient-reported EORTC QLQ-CIPN20 to assess PN, whereas it has been advised to combine self-reported PN measures with clinician-rated neurological assessment tools [42]. Nevertheless, we think that a patient-reported measure of PN is more reliable, as healthcare professionals often underestimate PN severity and objective measurements are often too insensitive to detect beginning or mild PN [43, 44]. The EORTC QLQ-CIPN20 is also the most implemented patient-reported measure of PN, with good psychometric properties, and we adhered to recent guidelines that advised to take caution with the use of its hearing problems item [31]. Another limitation is that we do not know why some patients stopped participating in our study. A previous study found that participants who were lost to follow-up in the PROFILES registry reported significantly worse HRQoL, functioning, and psychosocial symptoms [45]. For example, in our study, patients could have stopped participating because of severe PN symptoms in hands, which could have led to an underestimation of PN prevalence. Finally, generalization of the findings of this study should be done with caution, as eligible patients and participants differed in some sociodemographic and clinical characteristics. Despite these limitations, this study provides important insights in the role of mindfulness in chronic PN and impairments in related PROs. To the best of our knowledge, this is the first study on the role of mindfulness in chronic PN, including both painful and non-painful symptoms, and that examined both the cross-sectional and prospective association between mindfulness and chronic PN and impairments in related PROs. Future, longitudinal studies are warranted that also examine the role of mindfulness in the transition from acute to chronic PN.
In conclusion, the results of this prospective, population-based study among CRC patients showed that higher mindfulness at 1-year follow-up was associated with less severe PN, anxiety, and depressive symptoms, better sleep quality, and less fatigue. Future studies are needed that examine the role of mindfulness in the transition from acute to chronic PN.
Acknowledgements
We would like to thank all patients and their physicians for their participation in PROCORE. Special thanks go to C. Rolf, MD, and F. van Heest, MD, who were willing to function as independent advisors and to answer questions of patients. In addition, we want to thank the following hospitals for their collaboration: Elisabeth-TweeSteden Hospital, Tilburg; Catharina Hospital, Eindhoven; Elkerliek Hospital, Helmond; Máxima Medical Centre, Eindhoven and Veldhoven.
Abbreviations
- ACT
Acceptance and commitment therapy (ACT)
- CRC
Colorectal cancer
- MPN
Motor peripheral neuropathy
- NCR
Netherlands Cancer Registry
- PROs
Patient-reported outcomes
- PROFILES
Patient-Reported Outcomes Following Initial Treatment and Long-Term Evaluation of Survivorship
- PN
Peripheral neuropathy
- SPN
Sensory peripheral neuropathy
Author contribution
Conceptualization and study design: Cynthia S. Bonhof and Floortje Mols. Data collection: Cynthia S. Bonhof, Ignace H. de Hingh, Gerard Vreugdenhil, and Floortje Mols. Formal analysis: Cynthia S. Bonhof. Writing original draft: Cynthia S. Bonhof. Writing-review and editing: Cynthia S. Bonhof, Lonneke V. van de Poll-Franse, Ignace H. de Hingh, Gerard Vreugdenhil, and Floortje Mols. Supervision: Floortje Mols.
Funding
The present research was supported by the Center of Research on Psychological Disorders and Somatic Diseases (CoRPS), Tilburg University, The Netherlands; the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands; and an Investment Subsidy Large (2016/04981/ZONMW-91101002) of the Netherlands Organization for Scientific Research (The Hague, The Netherlands).
Data availability
The data that support the findings of this study are available from the PROFILES Registry (www.profilesregistry.nl).
Code availability
Not applicable.
Declarations
Competing interests
The authors declare no competing interests.
Ethics approval
The PROCORE study was approved by the certified Medical Ethic Committee of Medical Research Ethics Committees United (registration number NL51119.060.14).
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Consent for publication
Patients signed informed consent regarding publishing their data.
Conflict of interest
The authors declare no competing interests.
Footnotes
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Gutiérrez-Gutiérrez G, et al. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol. 2010;12(2):81–91. doi: 10.1007/S12094-010-0474-z. [DOI] [PubMed] [Google Scholar]
- 2.Seretny M, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461–2470. doi: 10.1016/j.pain.2014.09.020. [DOI] [PubMed] [Google Scholar]
- 3.Boyette-Davis JA, et al. Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy. Clin Cancer Res. 2012;18(11):3180–3187. doi: 10.1158/1078-0432.CCR-12-0205. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Bao T, et al. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat. 2016;159(2):327–333. doi: 10.1007/s10549-016-3939-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Bonhof CS, et al. Anxiety and depression mediate the association between chemotherapy-induced peripheral neuropathy and fatigue: results from the population-based PROFILES registry. Psychooncology. 2019;28(9):1926–1933. doi: 10.1002/pon.5176. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Hong JS, Tian J, Wu LH. The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients. Curr Oncol. 2014;21(4):174–180. doi: 10.3747/co.21.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Tofthagen C, et al. Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer. 2013;21(12):3307–3313. doi: 10.1007/s00520-013-1905-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Bonhof CS et al (2021) Association between peripheral neuropathy and sleep quality among colorectal cancer patients from diagnosis until 2-year follow-up: results from the PROFILES registry. J Cancer Surviv Nov 19. Epub ahead of print [DOI] [PubMed]
- 9.Loprinzi CL, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO Guideline Update. J Clin Oncol. 2020;38(28):3325–3348. doi: 10.1200/JCO.20.01399. [DOI] [PubMed] [Google Scholar]
- 10.Crombez G, et al. Fear-avoidance model of chronic pain: the next generation. Clin J Pain. 2012;28(6):475–483. doi: 10.1097/AJP.0b013e3182385392. [DOI] [PubMed] [Google Scholar]
- 11.Gatchel RJ, et al. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol Bull. 2007;133(4):581–624. doi: 10.1037/0033-2909.133.4.581. [DOI] [PubMed] [Google Scholar]
- 12.Curtin KB, Norris D. The relationship between chronic musculoskeletal pain, anxiety and mindfulness: adjustments to the fear-avoidance model of chronic pain. Scand J Pain. 2017;17(1):156–166. doi: 10.1016/j.sjpain.2017.08.006. [DOI] [PubMed] [Google Scholar]
- 13.Park SJ, et al. Factors associated with increased risk for pain catastrophizing in patients with chronic neck pain: a retrospective cross-sectional study. Medicine. 2016;95(37):e4698. doi: 10.1097/MD.0000000000004698. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Pulvers K, Hood A. The role of positive traits and pain catastrophizing in pain perception. Curr Pain Headache Rep. 2013;17(5):330. doi: 10.1007/s11916-013-0330-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Schütze R, et al. Low mindfulness predicts pain catastrophizing in a fear-avoidance model of chronic pain. Pain. 2010;148(1):120–127. doi: 10.1016/j.pain.2009.10.030. [DOI] [PubMed] [Google Scholar]
- 16.Bishop SR, et al. Mindfulness: a proposed operational definition. Clin Psychol Sci Pract. 2004;11(3):230–241. doi: 10.1093/clipsy.bph077. [DOI] [Google Scholar]
- 17.Baer RA. Measuring mindfulness. Contemp Buddhism. 2011;12(1):241–261. doi: 10.1080/14639947.2011.564842. [DOI] [Google Scholar]
- 18.Hilton L, et al. Mindfulness meditation for chronic pain: systematic review and meta-analysis. Ann Behav Med. 2017;51(2):199–213. doi: 10.1007/s12160-016-9844-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Pleman B, et al. Mindfulness is associated with psychological health and moderates the impact of fibromyalgia. Clin Rheumatol. 2019;38(6):1737–1745. doi: 10.1007/s10067-019-04436-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Senders A, et al. Association between pain and mindfulness in multiple sclerosis: a cross-sectional survey. Int J MS Care. 2018;20(1):28–34. doi: 10.7224/1537-2073.2016-076. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Zimmaro LA, et al. Greater mindfulness associated with lower pain, fatigue, and psychological distress in women with metastatic breast cancer. Psychooncology. 2020;29(2):263–270. doi: 10.1002/pon.5223. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Poulin PA, et al. The relationship between mindfulness, pain intensity, pain catastrophizing, depression, and quality of life among cancer survivors living with chronic neuropathic pain. Support Care Cancer. 2016;24(10):4167–4175. doi: 10.1007/s00520-016-3243-x. [DOI] [PubMed] [Google Scholar]
- 23.van de Poll-Franse LV, et al. The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer. 2011;47(14):2188–2194. doi: 10.1016/j.ejca.2011.04.034. [DOI] [PubMed] [Google Scholar]
- 24.Nederlandse Kankerregistratie. Cijfers over Kanker. [cited 2021 Sept 07]; Available from: http://www.cijfersoverkanker.nl/
- 25.Bonhof CS, et al. The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients. J Cancer Surviv. 2021;15(2):190–200. doi: 10.1007/s11764-020-00923-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Trompetter HR et al (2021) Exploring the relationship among dispositional optimism, health-related quality of life, and CIPN severity among colorectal cancer patients with chronic peripheral neuropathy. Support Care Cancer 30(1):95–104 [DOI] [PMC free article] [PubMed]
- 27.Sangha O, et al. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003;49(2):156–163. doi: 10.1002/art.10993. [DOI] [PubMed] [Google Scholar]
- 28.Carlson LE, Brown KW. Validation of the Mindful Attention Awareness Scale in a cancer population. J Psychosom Res. 2005;58(1):29–33. doi: 10.1016/j.jpsychores.2004.04.366. [DOI] [PubMed] [Google Scholar]
- 29.Postma TJ, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005;41(8):1135–1139. doi: 10.1016/j.ejca.2005.02.012. [DOI] [PubMed] [Google Scholar]
- 30.Fayers PM et al (2001) The EORTC QLQ-C30 Scoring Manual (3rd Edn). European Organisation for Research and Treatment of Cancer: Brussels
- 31.Smith EML, et al. Psychometric testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale using pooled chemotherapy-induced peripheral neuropathy outcome measures standardization and Alliance for Clinical Trials in Oncology A151408 study data. Cancer Nurs. 2019;42(3):179–189. doi: 10.1097/NCC.0000000000000596. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x. [DOI] [PubMed] [Google Scholar]
- 33.Buysse DJ, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213. doi: 10.1016/0165-1781(89)90047-4. [DOI] [PubMed] [Google Scholar]
- 34.Niezgoda HE, Pater JL. A validation study of the domains of the core EORTC quality of life questionnaire. Qual Life Res. 1993;2(5):319–325. doi: 10.1007/BF00449426. [DOI] [PubMed] [Google Scholar]
- 35.Bonhof CS, et al. Symptoms of pre-treatment anxiety are associated with the development of chronic peripheral neuropathy among colorectal cancer patients. Support Care Cancer. 2022;30(6):5421–5429. doi: 10.1007/s00520-022-06971-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Pachman DR, et al. Clinical course of oxaliplatin-induced neuropathy: results from the Randomized Phase III Trial N08CB (Alliance) J Clin Oncol. 2015;33(30):3416–3422. doi: 10.1200/JCO.2014.58.8533. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Lee KM, et al. Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer. J Psychosom Res. 2018;108:14–19. doi: 10.1016/j.jpsychores.2018.02.012. [DOI] [PubMed] [Google Scholar]
- 38.Yoshino T, et al. Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 Months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial. JAMA Oncol. 2019;5(11):1574–1581. doi: 10.1001/jamaoncol.2019.2572. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Sullivan MJL et al (2001) Theoretical perspectives on the relation between catastrophizing and pain. Clin J Pain 17(1):52–64 [DOI] [PubMed]
- 40.Nathan HJ, et al. Randomized trial of the effect of mindfulness-based stress reduction on pain-related disability, pain intensity, health-related quality of life, and A1C in patients with painful diabetic peripheral neuropathy. Clin Diabetes. 2017;35(5):294–304. doi: 10.2337/cd17-0077. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Veehof MM, et al. Acceptance- and mindfulness-based interventions for the treatment of chronic pain: a meta-analytic review. Cogn Behav Ther. 2016;45(1):5–31. doi: 10.1080/16506073.2015.1098724. [DOI] [PubMed] [Google Scholar]
- 42.Park SB, et al. Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2019;24(Suppl 2):S13–s25. doi: 10.1111/jns.12333. [DOI] [PubMed] [Google Scholar]
- 43.Cavaletti G, et al. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer. 2010;46(3):479–494. doi: 10.1016/j.ejca.2009.12.008. [DOI] [PubMed] [Google Scholar]
- 44.Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol. 2010;6(12):657–666. doi: 10.1038/nrneurol.2010.160. [DOI] [PubMed] [Google Scholar]
- 45.Ramsey I, et al. Cancer survivors who fully participate in the PROFILES registry have better health-related quality of life than those who drop out. J Cancer Surviv. 2019;13(6):829–839. doi: 10.1007/s11764-019-00793-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data that support the findings of this study are available from the PROFILES Registry (www.profilesregistry.nl).
Not applicable.